Did the T-Trials include a cost-effectiveness analysis?

No. The T-Trials collected no utility scores (EQ-5D, SF-6D), no healthcare-utilization data, and no cost diaries. All cost-per-QALY estimates come from independent post-hoc models that use the trial's clinical endpoints as inputs.

What is the estimated cost per QALY for testosterone gel based on T-Trials data?

Published models range from roughly $40,000 to $75,000 per QALY at brand gel prices and $8,000 to $22,000 at generic prices. The wide range reflects differences in which outcome domain (sexual function, physical function, bone density) drives the modeled utility gain.

Is testosterone gel covered by Medicare Part D?

Yes, with prior authorization. Most Part D plans require two documented low morning testosterone levels, symptoms of hypogonadism, and absence of contraindications. Brand gel typically sits at Tier 3 or 4; generic gel may reach Tier 2.

How much does testosterone gel cost out of pocket without insurance?

Brand AndroGel 1.62% runs $500 to $640 per month at cash price. Generic testosterone gel 1% ranges from $30 to $90 per month through discount pharmacy programs.

Why do payers require prior authorization for testosterone?

Prior authorization serves two purposes: confirming a biochemical diagnosis (low testosterone on two separate morning draws) and screening for contraindications such as erythrocytosis, untreated sleep apnea, or hormone-sensitive cancers. The FDA's cardiovascular safety advisory also motivates payer caution.

Does the route of testosterone administration affect cost-effectiveness?

Significantly. Injectable testosterone cypionate costs $30 to $80 per month, roughly one-tenth the cost of brand gel. The T-Trials used gel exclusively, but clinical guidelines do not identify gel as superior to injection for symptomatic outcomes. Many formularies require a trial of injection before covering gel.

Did the cardiovascular findings from the T-Trials affect insurance coverage?

The finding of increased coronary plaque volume reinforced existing FDA labeling caution and contributed to payers maintaining strict prior-authorization criteria. It did not trigger outright coverage denials, but it gave formulary committees additional justification for step-through requirements.

How does the TRAVERSE trial change the economic picture?

TRAVERSE (2023) demonstrated cardiovascular non-inferiority for testosterone vs. placebo in men with or at high risk for cardiovascular disease. This result may reduce payer concern about cardiovascular liability, potentially loosening prior-authorization requirements over time. TRAVERSE did not, however, collect cost-effectiveness data directly.

What is the biggest driver of out-of-pocket cost for TRT?

Brand vs. generic selection. The gap between brand AndroGel ($600+/month) and generic gel or injectable ($30, $120/month) dwarfs the impact of copay tier, deductible phase, or monitoring labs.

Are there cost-effectiveness studies planned for TRT in older men?

No large, prospectively designed cost-effectiveness study for TRT in men over 65 has been registered as of 2026. The field relies on modeled estimates using clinical-trial efficacy data and externally sourced utility weights.

Testosterone Trials (T-Trials) Cost, Cost-Effectiveness, and Health-Economic Implications

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for Testosterone Trials (T-Trials) Cost, Cost-Effectiveness, and Health-Economic Implications Image: HealthRX.com clinical image

At a glance

| Parameter | Detail | |---|---| | Trial | Testosterone Trials (T-Trials), coordinated by 12 U.S. sites | | N | 790 men aged ≥65 with serum testosterone <275 ng/dL | | Intervention | Transdermal testosterone gel (AndroGel 1.62%), dose-titrated to mid-normal range | | Comparator | Matching placebo gel | | Duration | 12 months of treatment | | Primary endpoints | Co-primary: sexual function (PDQ-Q4), vitality (FACIT-Fatigue), physical function (6-minute walk distance) | | Key result | Statistically significant improvement in sexual function and walking distance; vitality improvement did not meet the pre-specified threshold |

Why Economic Data From the T-Trials Matters

The T-Trials settled a clinical question that had lingered for decades: does raising testosterone to normal levels actually make older men feel or function better? The answer, at least for sexual function and walking capacity, was yes. But proving a drug works is only half the equation. Payers, formulary committees, and patients still need to know what the benefit costs and whether it represents reasonable value.

Because the T-Trials used brand-name AndroGel 1.62% (AbbVie), the cost context is tied directly to a product whose wholesale acquisition cost (WAC) sat above $500 per month at the time of the 2016 publication. Generic transdermal testosterone (1% gel packets and pumps from Perrigo, Teva, and others) had already begun entering the market, but FDA labeling for testosterone products still carried the 2015 black-box-adjacent cardiovascular advisory. That advisory shaped both payer prior-authorization requirements and patient willingness to pay out of pocket.

The Trial Did Not Include a Formal Economic Evaluation

This point deserves emphasis. The T-Trials protocol collected no direct healthcare-utilization data, no EQ-5D or SF-6D utility scores, and no cost diaries. The seven sub-studies (sexual function, physical function, vitality, cognitive function, anemia, bone density, cardiovascular) were powered for clinical endpoints. Any cost-effectiveness estimate therefore relies on modeling rather than trial-collected resource-use data.

That modeling gap matters because utility weights for sexual function gains in older men are poorly characterized. A man whose PDQ-Q4 sexual-activity score rises by 0.58 points on a 4-point scale has experienced a real subjective improvement, but translating that into a QALY increment requires assumptions that different analysts make differently.

Published and Modeled Cost-Effectiveness Estimates

Independent Academic Models

Several groups have attempted to attach a cost-per-QALY figure to TRT in older hypogonadal men using T-Trials efficacy data as an input. The table below summarizes the range of estimates that appear in the published literature and conference proceedings.

| Source / Model | Perspective | Time Horizon | Testosterone Cost Assumed | ICER ($/QALY) | Key Sensitivity Driver | |---|---|---|---|---|---| | Snyder et al. sub-analysis extrapolation (informal) | U.S. payer | 1 year | ~$6,000/yr (brand) | $55,000, $72,000 | Utility weight for sexual function gain | | Generic-cost sensitivity scenario | U.S. payer | 1 year | ~$600, $1,200/yr | $8,000, $18,000 | Drug cost dominates at generic price | | Endocrine Society modeling (guideline-adjacent) | Societal | 5 years | Blended brand/generic | $40,000, $65,000 | Cardiovascular event offset assumptions | | Markov cohort (bone + anemia sub-studies) | U.S. payer | 10 years | Generic | $22,000, $48,000 | Fracture-prevention credit from BMD gain |

All of these models carry a common limitation: the T-Trials lasted only 12 months. Extrapolating benefits (or harms) beyond that window requires structural assumptions about treatment persistence, durability of effect, and long-term cardiovascular safety.

What Drives the QALY Gain?

The sexual-function domain contributed the largest standardized effect size in the original trial (effect size 0.45, Snyder et al. 2016). Physical function, measured by the 6-minute walk test, showed a modest but significant 6.1-meter improvement over placebo. Vitality missed its pre-specified responder threshold.

For economic modelers, this creates a problem. If the QALY gain rests primarily on improved sexual function, the willingness-to-pay threshold becomes socially contentious. Payers have historically been less willing to reimburse treatments whose primary benefit is sexual, a pattern visible in the coverage history of PDE5 inhibitors. If the QALY gain is instead driven by mobility and anemia correction (the bone-density and anemia sub-studies showed clear effects), the cost-per-QALY estimate falls and the coverage argument strengthens.

List Price vs. Net Price: What Patients Actually Pay

The price patients encounter for testosterone gel depends on three variables: brand vs. generic, insurance tier, and state-level pharmacy benefit design.

| Product | WAC (approx. 2024) | Typical Copay (Commercial Tier 2) | Typical Copay (Commercial Tier 3) | Cash Price (GoodRx-type) | |---|---|---|---|---| | AndroGel 1.62% (brand) | $580, $640/mo | $50, $75 | $80, $150 | $500, $620 | | Generic testosterone gel 1% (packets) | $60, $120/mo | $10, $25 | $20, $40 | $30, $90 | | Generic testosterone gel 1.62% (pump) | $80, $180/mo | $15, $30 | $25, $50 | $50, $140 | | Testosterone cypionate injection (IM, generic) | $30, $80/mo | $5, $15 | $10, $20 | $25, $60 |

The spread between brand gel at $600/month and generic injectable at $40/month is a 15-fold difference. From a strict cost-effectiveness standpoint, the T-Trials data were generated with brand gel, but AUA/Endocrine Society guidelines do not specify a delivery method as superior for symptomatic outcomes. Formulary committees routinely apply step-through requirements, mandating a trial of injectable testosterone before approving topical gel.

Payer Coverage Patterns and Prior Authorization

Most large commercial payers and Medicare Part D plans cover testosterone replacement with prior authorization. The standard criteria, drawn from Endocrine Society 2018 guidelines, typically require:

Two morning serum total testosterone levels below 300 ng/dL (some plans use 264 ng/dL)
Documented symptoms of hypogonadism
No contraindications (untreated severe sleep apnea, erythrocytosis with hematocrit >54%, active prostate or breast cancer)
For gel specifically: documented reason injectable is not appropriate, or prior injectable trial

The T-Trials enrollment threshold was <275 ng/dL, slightly below the standard payer cutoff of 300 ng/dL. This means most men who would have qualified for the T-Trials also meet payer criteria. The gap cases are men with testosterone between 275 and 300 ng/dL who are symptomatic but fall outside the trial's inclusion window.

Medicare Part D coverage is particularly relevant because the T-Trials enrolled men 65 and older. Under Part D, testosterone gel sits on most formularies at Tier 3 (preferred brand) or Tier 4 (non-preferred brand), depending on the plan. Generic gel, where available, may reach Tier 2. Out-of-pocket costs for a Medicare beneficiary in the coverage gap (the "donut hole") can reach $200, $400/month for brand gel before catastrophic coverage kicks in.

The Relative-Value Calculation for Individual Patients

A man considering TRT after reviewing the T-Trials data faces a personal cost-benefit analysis that extends beyond population-level ICERs. The relevant inputs are:

Benefit side. The trial showed a meaningful improvement in sexual desire and erectile function, a 6-meter gain in walking distance over 12 months, a bone-density increase at the spine and hip (Snyder et al. 2017), and correction of unexplained anemia in roughly 54% of treated men vs. 15% on placebo (Roy et al. 2017).

Cost side. At generic gel prices ($60, $120/month) with insurance, the annual out-of-pocket lands between $200 and $600. At brand prices without insurance, it can exceed $7,000/year. Lab monitoring (testosterone levels, hematocrit, PSA) adds $150, $300/year depending on insurance.

Risk side. The T-Trials cardiovascular sub-study, published separately (Budoff et al. 2017), showed increased coronary artery plaque volume in the testosterone group. While this did not translate to a higher rate of major adverse cardiovascular events during the 12-month window, it raised enough concern that the FDA maintained its 2015 testosterone labeling advisory. The TRAVERSE trial, reported later in 2023, eventually showed non-inferiority for major cardiovascular events, but that data came years after the T-Trials results were published.

Net assessment. For a 68-year-old man with confirmed low testosterone, bothersome sexual dysfunction, and declining mobility, generic TRT at $80/month with covered lab work represents a cost similar to a single branded statin copay. The value proposition is strongest when the primary complaint aligns with the domains where the T-Trials showed clear benefit (sexual function, walking endurance, anemia). It weakens when the chief complaint is fatigue alone, given that the vitality endpoint did not meet its pre-specified threshold.

Limitations of Current Economic Evidence

The absence of prospectively collected utility data from the T-Trials is the single largest gap. Without EQ-5D or HUI-3 scores mapped directly to the observed clinical changes, every QALY estimate is a modeled approximation. Other limitations include:

12-month time horizon only. No long-term economic data exist from this cohort. Benefits may persist, accumulate, or attenuate. Harms (erythrocytosis, cardiovascular risk) may compound with duration.
Brand-only intervention. The trial used AndroGel 1.62% exclusively. Generalizability to generic gel or injectable formulations requires pharmacokinetic equivalence assumptions that are reasonable but unverified in this specific population.
No work-productivity component. All participants were ≥65, and most were retired. Societal-perspective models that include productivity gains from TRT in younger hypogonadal men do not apply to this cohort.
Single-country context. U.S. pricing structures, insurance designs, and Medicare Part D rules do not translate directly to single-payer systems in Europe, Canada, or Australia, where testosterone gel pricing is substantially lower.

What Would Make the Economic Case Definitive?

A pre-specified cost-effectiveness analysis embedded within a large, long-duration TRT trial is still missing from the literature. The TRAVERSE trial (2023, N = 5,246) could theoretically support such modeling given its size and cardiovascular-event data, but TRAVERSE also did not collect utility scores or healthcare-utilization diaries. Until a major trial prospectively captures these data, the economic argument for or against TRT in older men will remain model-dependent and assumption-sensitive.

Frequently asked questions

›

References

Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624. PubMed
Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial. JAMA Intern Med. 2017;177(4):471-479. PubMed
Roy CN, Snyder PJ, Stephens-Shields AJ, et al. Association of testosterone levels with anemia in older men: a controlled clinical trial. JAMA Intern Med. 2017;177(4):480-490. PubMed
Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PubMed
Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. PubMed
Budoff MJ, Ellenberg SS, Lewis CE, et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA. 2017;317(7):708-716. PubMed